The first participant has been enrolled in a Phase 3 clinical trial evaluating Ofev (nintedanib) in children with…
Articles by Marisa Wexler, MS
People with idiopathic pulmonary fibrosis (IPF) are at increased risk of several cancers other than lung cancer, a new…
The European Commission has approved Boehringer Ingelheim‘s Ofev (nintedanib)Â for the treatment of progressive fibrosing interstitial…
The protein granulocyte-colony stimulating factor (G-CSF) inhibited fibrosis in a mouse model of pulmonary fibrosis, a new study…
A new molecular probe could aid in studies of pulmonary fibrosis and other fibrotic diseases, a study reports. The…
The Open Source Imaging Consortium (OSIC), a nonprofit collaborative group focused on combatting lung diseases, has launched a competition…
New preclinical data support MRG-229, an investigative next-generation treatment for idiopathic pulmonary fibrosis (IPF), as safe and effective, miRagen reported. “We believe…
Severe fatigue is common among people with idiopathic pulmonary fibrosis (IPF) and pulmonary sarcoidosis, and is associated with…
Across the world, a fair amount of variation exists in medical practices to diagnose and treat acute exacerbations of…
Abnormal buildup of iron in the lungs can cause lung fibrosis (scarring), and targeting this accumulation could be a therapeutic…